bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: D N O S A J J M A M F J
2013: D

 
  Other news for:
Surgery
 Resources from HONselect
Implantable Heart Devices Work, Regardless of Race: Study
Previous research into benefits hadn't included large numbers of minorities

By Robert Preidt

MONDAY, Aug. 18, 2014 (HealthDay News) -- Implantable heart devices are as effective in reducing the risk of death in minority patients with heart failure as in white patients, a new study says.

While these devices are recommended for all eligible patients, previous research has shown that black and Hispanic patients were not well-represented in past clinical trials and are less likely than whites to receive implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices.

In this large study, researchers followed more than 15,000 heart failure patients over two years and found that those who received ICDs had a 36 percent lower risk of death, regardless of race or ethnicity.

The researchers also found that the use of CRT therapy reduced the risk of death by 45 percent, regardless of race or ethnicity, according to the study in the Aug. 26 issue of the Journal of the American College of Cardiology. The study was funded by medical device maker Medtronic Inc.

"This is among the largest studies to address the question of race- and ethnicity-specific benefits with ICD or CRT therapies in real-world practice," senior author Dr. Gregg Fonarow, a professor of cardiology and director of the Cardiomyopathy Center at the University of California, Los Angeles, said in a university news release.

"Our results are a reminder to physicians and patients that this proven life-extending therapy should be offered to all eligible heart failure patients without regard for race or ethnicity," added Fonarow, who is a consultant with Medtronic.

More than 5 million Americans have heart failure, which puts them at high risk of sudden death.

"Implantable devices are proven to save the lives of heart failure patients and should be offered to all patients who qualify, without consideration of race or ethnicity, to ensure more equitable benefit from this life-saving therapy," study first author Dr. Boback Ziaeian, a UCLA cardiologist, said in the news release.

The study was coordinated by 10 academic medical centers, including UCLA.

More information

The U.S. National Library of Medicine has more about heart failure.

SOURCE: University of California, Los Angeles, news release, Aug. 18, 2014

Copyright © 2014 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=690885

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Heart
Equipment and Supplies
Heart Failure, Congestive
Death
Risk
Research Personnel
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact